NASDAQ:AYLA

Ayala Pharmaceuticals News Headlines

$2.00

-0.05 (-2.44%)

(As of 05/13/2022 03:59 PM ET)

Add

Compare

Today's Range: $1.97
▼
$2.30
50-Day Range: $2.00
▼
$4.30
52-Week Range: $1.97
▼
$14.95

Volume: 15,600 shs
Average Volume: 29,479 shs
Market Capitalization: $28.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 1.39

Get Ayala Pharmaceuticals News Delivered to You Automatically

Media Mentions By Week

Ayala Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AYLA
News Sentiment
▼
1.29

0.48
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AYLA Articles
This Week
▼
3

0
▲
AYLA Articles
Average Week

Ayala Pharmaceuticals (NASDAQ:AYLA) News Headlines Today

Source

Source	Headline
	Short Interest in Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Decreases By 63.6% americanbankingnews.com - May 12 at 4:54 AM
	Short Interest in Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Expands By 33.3% americanbankingnews.com - May 2 at 4:46 AM
	Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - April 27 at 1:49 PM
	Ayala Pharmaceuticals GAAP EPS of -$2.80, revenue of $3.5M seekingalpha.com - March 30 at 9:51 PM
	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates msn.com - March 28 at 7:10 PM
	Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update finance.yahoo.com - March 28 at 7:10 PM
	Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference finance.yahoo.com - March 9 at 9:00 AM
	Ayala Pharmaceuticals (NASDAQ:AYLA) Will Have To Spend Its Cash Wisely finance.yahoo.com - March 3 at 8:41 AM
	Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors finance.yahoo.com - February 23 at 12:20 PM
	Ayala Pharmaceuticals, Inc. Common Stock (AYLA) nasdaq.com - January 19 at 11:33 PM
	Buy These 2 Small-Cap Stocks to Double Your Investment, Say Analysts finance.yahoo.com - January 17 at 6:40 PM

	Ayala Pharmaceuticals Inc Shares Fall 4.6% Below Previous 52-Week Low - Market Mover nasdaq.com - January 13 at 7:29 PM
	Ayala Pharmaceuticals Inc Shares Fall 4.3% Below Previous 52-Week Low - Market Mover nasdaq.com - January 7 at 11:31 PM
	Ayala Pharmaceuticals Announces Key Business Objectives for 2022 finance.yahoo.com - January 4 at 12:27 PM
	How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116% finance.yahoo.com - November 18 at 12:57 PM
	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com - November 15 at 3:03 PM
	Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update finance.yahoo.com - November 15 at 8:35 AM
	Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference finance.yahoo.com - November 10 at 8:20 AM
	Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline nasdaq.com - November 9 at 5:07 PM
	Ayala Pharmaceuticals Inc. barrons.com - October 7 at 11:31 PM
	Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101 finance.yahoo.com - September 16 at 8:44 PM
	Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC finance.yahoo.com - September 16 at 10:32 AM
	Investors in Ayala Pharmaceuticals (NASDAQ:AYLA) have made a respectable return of 51% over the past year nasdaq.com - September 7 at 8:27 AM
	Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 finance.yahoo.com - September 1 at 8:54 AM
	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates finance.yahoo.com - August 13 at 3:21 PM
	Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know finance.yahoo.com - August 5 at 8:03 PM
	We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully finance.yahoo.com - July 29 at 9:58 AM
	Is AYLA Stock A Buy Here? finance.yahoo.com - June 18 at 2:34 PM
	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - May 14 at 2:22 PM
	Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update finance.yahoo.com - May 14 at 9:21 AM
	Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma finance.yahoo.com - April 21 at 12:34 PM
	Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update finance.yahoo.com - March 25 at 9:10 AM
	Ayala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of Shares finance.yahoo.com - February 24 at 11:15 PM

	Ayala Pharmaceuticals raises $25M from private stock sale bizjournals.com - February 24 at 6:15 PM
	Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16% finance.yahoo.com - February 22 at 1:13 PM
	Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors finance.yahoo.com - February 19 at 2:34 PM
	Companies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In Growth finance.yahoo.com - February 19 at 9:33 AM
	ACIU & Alzheimer's Vaccine, GNMK Rallies, ESSA's Prostate Cancer Drug On Track, MNPR On Watch nasdaq.com - February 12 at 7:35 AM
	NVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial nasdaq.com - January 29 at 2:14 AM
	Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer finance.yahoo.com - January 28 at 11:10 AM
	Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference finance.yahoo.com - January 13 at 8:55 PM
	Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference finance.yahoo.com - January 5 at 11:57 AM
	Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study finance.yahoo.com - January 4 at 12:53 PM
	Ayala Pharmaceuticals Inc reuters.com - December 16 at 7:44 AM
	Growth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64% nasdaq.com - November 20 at 10:08 AM
	Ayala Pharmaceuticals EPS misses by $0.03, beats on revenue seekingalpha.com - November 19 at 8:40 AM
	Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update finance.yahoo.com - November 17 at 9:49 AM
	Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences finance.yahoo.com - November 5 at 9:48 AM
	Ayala Pharma under pressure on underwhelming AL101 data in type of cancer affecting the glandular tissues seekingalpha.com - September 18 at 1:46 PM
	Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020 finance.yahoo.com - September 18 at 8:45 AM

Get Ayala Pharmaceuticals News Delivered to You Automatically

This page was last updated on 5/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources